Updated: May 25, 2021

Since the hemp legalization in 2018, there's an increased interest in the Cannabis plant and its compounds. Experts from various sectors like wellness, health, nutrition, and others embrace it in a big way. While CBD (cannabidiol) and THC (tetrahydrocannabinol) are the two most popular cannabinoids, many other ones are worth learning about. One of

the lesser-known cannabinoid but with huge potential is CBG (cannabigerol), which has recently caught the experts' attention.


CBG is a nonintoxicating minor cannabinoid naturally occurring in the Cannabis plant. It is often referred to as the “mother of all cannabinoids” because several cannabinoids start as CBGA (cannabigerolic acid) - an acidic form of CBG.

When the plant starts to mature, specific enzymes will break down most of the CBGA into three main lines: CBDA (cannabidiolic acid), THCA (tetrahydrocannabinolic acid), and CBCA (cannabichromenic acid). When the acids are exposed to light or heat, a process called decarboxylation will convert them into cannabinoids we know CBD and THC. The same process converts CBGA into CBG, but at a much lower scale; thus, the cannabigerol concentration in the cannabis plant is low, usually around 1%.

To achieve higher yields of CBG, breeders are experimenting with genetic manipulation and cross-breeding of the plants. Scientists also determined that it’s possible to extract higher levels of CBG by identifying the optimum extraction time in the flowering cycle.

Because CBG is difficult and expensive to extract in considerable amounts, products using it as the main ingredient are rare. Instead, it’s often combined with other cannabinoids to create the “entourage effect” and bring additional benefits.


CBG is processed by the body’s Endocannabinoid System (ECS), which is a complex biological system that works to keep the body in its balanced state of homeostasis. ECS has receptors spread through the body to which endocannabinoids bind.

There are two types of receptors, CB1 and CB2:

CB1 receptors are located mainly in the central nervous system and responsible for managing coordination, mood, appetite, memory, etc. CB2 receptors are located in the peripheral nervous system, influencing pain and inflammation.

Endocannabinoids are molecules produced by the human body that keep internal functions running smoothly.

CBG imitates the endocannabinoids and binds to both types of receptors, helping with a range of conditions.


CBG is by far studied less than CBD or THC; however, the preliminary results look promising. We need to understand that most of the studies are done on animals using large doses of isolated CBG. They don’t provide conclusive evidence that CBG products can treat any human diseases. There’s still much research to be done on the subject. Still, with the few completed studies on humans, we can expect that CBG might help the following therapeutic benefits listed below.

Inflammatory Bowel Disease (IBD)

Inflammatory Bowel Disease is characterized by chronic inflammation of the gastrointestinal tract.

An animal study involving mice observed the beneficial effects of cannabigerol on IBD. Researchers induced inflammations similar to IBD in the colons of mice and then administered CBG. They found that CBG helped reduce inflammation and the production of nitric oxide.


Glaucoma is a set of eye conditions that damages the optic nerve, which connects the eye to the brain. High pressure in the eye commonly causes this damage, and it might lead to loss of vision.

In an animal study, CBG was found to be effective in treating these conditions. Researchers administered CBG to cats with glaucoma and noticed a reduction in eye pressure. They also saw an increase in Aqueous Humor Outflow, a fluid produced by the eye which provides the eye with nutrition and maintains eye pressure.

Huntington’s Disease

Huntington's Disease is characterized by the progressive breakdown (degeneration) of nerve cells in the brain.

In a 2015 study on mice with the Disease's experimental model, researchers examined the potential neuroprotective properties of CBG and other cannabinoids. They have noticed that CBG acted as a neuroprotectant, shielding the brain's nerve cells from damage.

Killing Cancer Cells

CBG is showing some great promise as a cancer fighter. A 2020 study conducted by Cannabics Pharmaceuticals shown that CBG exhibits anti-tumor properties. They conducted a series of tests to screen the necrotic effects of different cannabinoids on human Gastrointestinal Cancer Cells., in addition to other cancer types previously tested. CBG and CBC were both shown to induce significantly higher necrosis rates (death of body tissue) in these cancer cells compared to other cannabinoids. Gastrointestinal cancers are amongst the most widespread causes of cancer-related deaths globally. These preliminary results are significant to continue the research and aim to explore the differential anti-tumor properties of cannabinoids further.


These two cannabinoids are often compared because they share some similarities, and they both act on the endocannabinoid system (ES). Both CBG and CBD are non-psychoactive, which means they won’t get you high. More than that, by binding with CB1 receptors that are located in the brain, they can reduce the effects of THC.

However, the slight molecular differences between the two cannabinoids result in significantly different effects. CBG is observed to bind well with the ES receptors, and, as a result, it might cause a direct response. By contrast, CBD has a lower affinity but acts on the receptors differently. Instead of binding with the receptors, they may block them from interacting with other substances. The most significant difference, though, between them is the quantity found in the cannabis plant. Most cannabis plants contain only 1% of CBG but up to 25% of CBD.


Because of its scarcity and production difficulties, CBG can get very expensive. Manufacturers will combine it with other cannabinoids to reduce the cost and to bring additional effects.

Our CBG & CBD Topicals contain a high concentration of both cannabinoids for better results. CBG also binds with the CB2 receptors located on the skin delivering the results faster and more effectively.

CBG is often used for making “smokables,” and it’s usually combined with Delta 8 and CBD to create the Entourage Effect.

You can also find small amounts of CBG alongside dozens of other cannabinoids in all full-spectrum and broad-spectrum hemp products in our store.


CBG can be lawfully produced and extracted from hemp under the 2018 Farm Bill. Unlike CBD, CBG has not been approved as a drug. FDA itself has acknowledged that “parts of the cannabis plant that do not contain THC or CBD might fall outside the scope of the [drug exclusion rule].” If CBG will be approved as a drug in the future, it’s also possible that the drug exclusion rule won’t apply; this is because the law contains an exception for substances marketed as foods or dietary supplements before any FDA clinical investigation. Companies are already selling CBG products as foods and nutritional supplements.


Because it is non-psychotropic, CBG has a promising wide range of potential applications for the problems mentioned above and as an analgesic, therapy for psoriasis, and an antidepressant. However, more research needs to be done into easing the production and

availability of this cannabinoid.

10 views0 comments

Recent Posts

See All